A randomized Phase II study of interleukin-2 with and without beta-interferon for patients with advanced non-small cell lung cancer. An Eastern Cooperative Oncology Group study (PZ586)

William J. Tester, Kyung Mann Kim, Robert L. Krigel, Philip D. Bonomi, John H. Glick, Robert F. Asbury, John M. Kirkwood, Ronald H. Blum, Joan H. Schiller

Research output: Contribution to journalArticle

18 Scopus citations

Abstract

Interleukin-2 (IL-2) and beta-interferon (β-IFN) are biologic agents with antitumor activity observed in preclinical models. Some studies of patients with advanced non-small cell lung cancer treated with IL-2 report relatively long survival, despite low response rates. Seventy-six evaluable patients with stage IV non-small cell lung cancer were treated in a randomized Phase II study with either IL-2 alone or IL-2 plus β-IFN. Patients received either IL-2 at 6x106 Cetus units/m2 3 days weekly or the combination of IL-2 at 5x106 Cetus units/m2 plus β-IFN at 6x106 units/m2, both given 3 days weekly. Both biologic agents were administered by intravenous bolus injection on an outpatient basis. Objective responses were observed in 3/76 (4%) patients. Grade 4 toxicity occurred in 3/39 patients treated with IL-2 alone, and in 4/37 patients treated with IL-2 plus β-IFN. An additional lethal respiratory toxicity occurred in a patient who received IL-2 plus β-IFN. The median survival of all patients treated on this study was 33 weeks. Despite producing only a 4% objective response rate, IL-2 appears to have a favorable impact on survival comparable to chemotherapy. The role for this immune therapy in the management of non-small cell lung cancer requires further study. Copyright (C) 1999 Elsevier Science Ireland Ltd.

Original languageEnglish (US)
Pages (from-to)199-206
Number of pages8
JournalLung Cancer
Volume25
Issue number3
DOIs
StatePublished - Sep 1 1999

Keywords

  • Beta-interferon
  • Interleukin-2
  • Non-small cell lung cancer

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Fingerprint Dive into the research topics of 'A randomized Phase II study of interleukin-2 with and without beta-interferon for patients with advanced non-small cell lung cancer. An Eastern Cooperative Oncology Group study (PZ586)'. Together they form a unique fingerprint.

  • Cite this

    Tester, W. J., Kim, K. M., Krigel, R. L., Bonomi, P. D., Glick, J. H., Asbury, R. F., Kirkwood, J. M., Blum, R. H., & Schiller, J. H. (1999). A randomized Phase II study of interleukin-2 with and without beta-interferon for patients with advanced non-small cell lung cancer. An Eastern Cooperative Oncology Group study (PZ586). Lung Cancer, 25(3), 199-206. https://doi.org/10.1016/S0169-5002(99)00054-9